Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis

68Citations
Citations of this article
74Readers
Mendeley users who have this article in their library.

Abstract

The development of the hematopoietic system is a dynamic process that is controlled by the interplay between transcriptional and epigenetic networks to determine cellular identity. These networks are critical for lineage specification and are frequently dysregulated in leukemias. Here, we identified histone demethylase KDM2B as a critical regulator of definitive hematopoiesis and lineage commitment of murine hematopoietic stem and progenitor cells (HSPCs). RNA sequencing of Kdm2b-null HSPCs and genome-wide ChIP studies in human leukemias revealed that KDM2B cooperates with polycomb and trithorax complexes to regulate differentiation, lineage choice, cytokine signaling, and cell cycle. Furthermore, we demonstrated that KDM2B exhibits a dichotomous role in hematopoietic malignancies. Specifically, we determined that KDM2B maintains lymphoid leukemias, but restrains RAS-driven myeloid transformation. Our study reveals that KDM2B is an important mediator of hematopoietic cell development and has opposing roles in tumor progression that are dependent on cellular context.

Cite

CITATION STYLE

APA

Andricovich, J., Kai, Y., Peng, W., Foudi, A., & Tzatsos, A. (2016). Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis. Journal of Clinical Investigation, 126(3), 905–920. https://doi.org/10.1172/JCI84014

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free